In The News
December 14, 2020

2020 Was the Turning Point for CRISPR

Medium – Future Human – Scribe Therapeutics of Alameda, California, is using yet another form of CRISPR dubbed X-editing. Co-founded by CRISPR pioneer and Nobel winner Jennifer Doudna, PhD, the company will use the new gene-editing tool to develop treatments for neurological diseases.

Read More
November 3, 2020

Doudna’s Scribe unveils

Nature Biotechnology – Startup Scribe Therapeutics, spun out of Jennifer Doudna’s lab, emerged from stealth on 6 October with a next-generation CRISPR technology, armed with a $20-million series A round and a collaboration with Biogen.

Read More
October 20, 2020

8 Biocom Member Companies Leveraging CRISPR Technology

Biocom – Another of Doudna’s spin-outs, Scribe Therapeutics, just recently announced their plans to build a platform for CRISPR-based genetic medicine to create therapies for diseases like genetically driven ALS. The company’s tools and mission have the potential to dramatically accelerate CRISPR’s applications into the clinical setting.

Read More
October 8, 2020

CRISPR-Based ALS Treatment Being Developed by Scribe and Biogen

Genetic Engineering & Biotechnology News – Best known for her pioneering work in the discovery of CRISPR, Jennifer Doudna, PhD, professor at the University of California, Berkeley, doesn’t stop or, it seems, even slow down. As of yesterday morning, Doudna can add “accept Nobel Prize” to her to-do list as she, along with Emmanuelle Charpentier, PhD, was awarded the 2020 Nobel Prize in Chemistry.

Read More
October 8, 2020

Scribe, Biogen Partner to Develop Gene Therapy for ALS, Other Neurological Diseases

ALS News Today – Founded by the scientists who originally invented CRISPR, Scribe has developed novel, custom-CRISPR tools, using a technology called X-Editing. This advanced gene-editing platform has greater editing activity and higher specificity, meaning that it can edit the target gene with greater precision than other CRISPR tools currently available.

Read More
Press Releases
More Headlines